<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01102270</url>
  </required_header>
  <id_info>
    <org_study_id>2008P000818</org_study_id>
    <secondary_id>1P01HL095491-01</secondary_id>
    <nct_id>NCT01102270</nct_id>
  </id_info>
  <brief_title>The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome</brief_title>
  <official_title>A Double-Blind Randomized Physiological Study Examining the Effects of Eszopiclone on the Arousal Threshold and Obstructive Sleep Apnea Severity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether taking eszopiclone (Lunesta) changes the
      breathing effort required to briefly wake people with obstructive sleep apnea from sleep
      (respiratory arousal threshold). We would like to see if taking eszopiclone can reduce the
      severity of obstructive sleep apnea in some people (those that have a low respiratory arousal
      threshold; i.e. wake up easily to respiratory stimuli).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obstructive sleep apnea is an exceedingly common disease with major neurocognitive and
      cardiovascular consequences. The current primary treatment e.g. Continuous positive airway
      pressure (CPAP) is effective but poorly tolerated by many patients particularly those with
      mild-moderate disease. Secondary treatments such as oral appliances to advance the mandible
      or surgical procedures to enlarge the airway are commonly appealing to the patient. However,
      these approaches have only modest success in reducing apnea frequency to an acceptable level.
      Thus, finding tolerable and effective therapy for sleep apnea remains an important objective.

      The causes of sleep apnea vary between patients. Targeted therapy according to the underlying
      causes of sleep apnea in individual patients is likely to be most effective. However, current
      therapeutic options for sleep apnea are quite limited. The purpose of this physiological
      research study is to determine if taking eszopiclone (Lunesta)changes the breathing effort
      required to briefly wake people with obstructive sleep apnea from sleep (the arousal
      threshold) and if administration of the sedative medication eszopiclone (Lunesta) to certain
      sleep apnea patients (those with a low arousal threshold ie wake up easily) would be
      beneficial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apnea Hypopnea Index</measure>
    <time_frame>8 hour In-Laboratory Polysomnogram (PSG)</time_frame>
    <description>number of respiratory events per hour of sleep Respiratory events last for at least 10 seconds and are associated with a decrease in blood oxygenation or a cortical arosual from sleep. AHI values are typically categorized as 5-15/hr = mild; 15-30/hr = moderate; and &gt; 30/h = severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arousal Threshold</measure>
    <time_frame>8 hour In-Laboratory Polysomnogram (PSG)</time_frame>
    <description>quantified using an epiglottic pressure transducer in CmH2O</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nadir Overnight Oxygen Saturation</measure>
    <time_frame>8 hour In-Laboratory Polysomnogram (PSG)</time_frame>
    <description>Nadir overnight oxygen saturation (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Duration</measure>
    <time_frame>8 hour In-Laboratory Polysomnogram (PSG)</time_frame>
    <description>total sleep duration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Eszopiclone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eszopiclone 3mg prior to sleep (1 night)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar Pill (placebo) prior to sleep (1 night)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eszopiclone</intervention_name>
    <description>3mg tablet once prior to sleep</description>
    <arm_group_label>Eszopiclone</arm_group_label>
    <other_name>Lunesta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 placebo capsule prior to sleep</description>
    <arm_group_label>Sugar Pill</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-64 years old

          -  Untreated obstructive sleep apnea

        Exclusion Criteria:

          -  Nadir SaO2 &lt;70% on a baseline PSG

          -  Medications known to affect either sleep, breathing or muscle activity

          -  Major co-morbidities apart from sleep apnea

          -  Allergy to lidocaine, oxymetazoline HCl, or eszopiclone

          -  Women who are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atul Malhotra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital, Division of Sleep Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Eckert DJ, Owens RL, Kehlmann GB, Wellman A, Rahangdale S, Yim-Yeh S, White DP, Malhotra A. Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold. Clin Sci (Lond). 2011 Jun;120(12):505-14. doi: 10.1042/CS20100588.</citation>
    <PMID>21269278</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2010</study_first_submitted>
  <study_first_submitted_qc>April 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2010</study_first_posted>
  <results_first_submitted>April 29, 2013</results_first_submitted>
  <results_first_submitted_qc>April 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 18, 2017</results_first_posted>
  <last_update_submitted>April 14, 2017</last_update_submitted>
  <last_update_submitted_qc>April 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Atul Malhotra, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Obstructive sleep apnea</keyword>
  <keyword>Arousal threshold</keyword>
  <keyword>Sedative medication</keyword>
  <keyword>upper airway</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eszopiclone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>published</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>subjects recruited 2008-2010 from clinics and ads</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Eszopiclone First, Then Sugar Pill</title>
          <description>Eszopiclone : 3mg tablet once prior to sleep followed by sugar pill (placebo) 1 week later</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill First, Then Eszopiclone</title>
          <description>Placebo : 1 placebo capsule prior to sleep then 3mg eszopiclone 1 week later</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>although 28 were screened, only 17 were randomized since 11 did not qualify for the randomization portion of the study</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>all study participants who received all interventions</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Arousal Threshold</title>
        <description>quantified using an epiglottic pressure transducer in CmH2O</description>
        <time_frame>8 hour In-Laboratory Polysomnogram (PSG)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone : 3mg tablet once prior to sleep</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo : 1 placebo capsule prior to sleep</description>
          </group>
        </group_list>
        <measure>
          <title>Arousal Threshold</title>
          <description>quantified using an epiglottic pressure transducer in CmH2O</description>
          <units>cmH2O</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18" lower_limit="-22.1" upper_limit="-15.1"/>
                    <measurement group_id="O2" value="-14" lower_limit="-19.9" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nadir Overnight Oxygen Saturation</title>
        <description>Nadir overnight oxygen saturation (%)</description>
        <time_frame>8 hour In-Laboratory Polysomnogram (PSG)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone : 3mg tablet once prior to sleep</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo : 1 placebo capsule prior to sleep</description>
          </group>
        </group_list>
        <measure>
          <title>Nadir Overnight Oxygen Saturation</title>
          <description>Nadir overnight oxygen saturation (%)</description>
          <units>% oxygen saturation</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" spread="1"/>
                    <measurement group_id="O2" value="80" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apnea Hypopnea Index</title>
        <description>number of respiratory events per hour of sleep Respiratory events last for at least 10 seconds and are associated with a decrease in blood oxygenation or a cortical arosual from sleep. AHI values are typically categorized as 5-15/hr = mild; 15-30/hr = moderate; and &gt; 30/h = severe</description>
        <time_frame>8 hour In-Laboratory Polysomnogram (PSG)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone : 3mg tablet once prior to sleep</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo : 1 placebo capsule prior to sleep</description>
          </group>
        </group_list>
        <measure>
          <title>Apnea Hypopnea Index</title>
          <description>number of respiratory events per hour of sleep Respiratory events last for at least 10 seconds and are associated with a decrease in blood oxygenation or a cortical arosual from sleep. AHI values are typically categorized as 5-15/hr = mild; 15-30/hr = moderate; and &gt; 30/h = severe</description>
          <units>events per hour of sleep</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="4"/>
                    <measurement group_id="O2" value="31" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Duration</title>
        <description>total sleep duration</description>
        <time_frame>8 hour In-Laboratory Polysomnogram (PSG)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone : 3mg tablet once prior to sleep</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo : 1 placebo capsule prior to sleep</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Duration</title>
          <description>total sleep duration</description>
          <units>hours of sleep</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="0.2"/>
                    <measurement group_id="O2" value="5.4" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Overnight study and the following morning</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Eszopiclone</title>
          <description>Eszopiclone : 3mg tablet once prior to sleep</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Placebo : 1 placebo capsule prior to sleep</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We excluded patients with blood arterial oxygen saturations &lt;70% as we wanted to avoid any potential risks associated with this group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Atul Malhotra</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>6177326488</phone>
      <email>amalhotra1@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

